Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616860 | 0.79 | CA9 (0.62) | TRPV1CA9SMYD3SMN1; SMN2KDM4E | |
| SCHEMBL13545275 | 0.79 | CA9 (0.57) | TRPV1CA9SMN1; SMN2KDM4ELMNA | |
| SCHEMBL23432587 | 0.75 | CA9 (0.53) | TRPV1CA9SMN1; SMN2KDM4ELMNA | |
| SCHEMBL8063798 | 0.75 | CA9 (0.53) | TRPV1CA9SMN1; SMN2KDM4ELMNA | |
| SCHEMBL89384 | 0.75 | SYK (0.36) | TRPV1CA9SMYD3MAPK14CRBN | |
| SCHEMBL89196 | 0.73 | GAA (0.60) | TRPV1SMYD3SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL8245548 | 0.73 | HTT (0.51) | TRPV1SMN1; SMN2LMNAKMT2AALDH1A1 | |
| SCHEMBL28778385 | 0.72 | CA9 (0.57) | TRPV1CA9SMYD3SMN1; SMN2KDM4E | |
| SCHEMBL29754420 | 0.72 | CA9 (0.57) | TRPV1CA9SMYD3SMN1; SMN2KDM4E | |
| SCHEMBL3596364 | 0.71 | HDAC3 (0.54) | TRPV1CA9SMN1; SMN2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| EP-2177518-A1 | Organic compounds | Novartis AG (CH) | 2010-04-21 | — | — | EP | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-1833816-B1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006069788-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | TRPV1 319/4885CA9 630/4885SMYD3 2084/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | TRPV1 220/4885CA9 611/4885SMYD3 2177/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | TRPV1 217/4885CA9 501/4885SMYD3 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.